PH1.

Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...

Akari Therapeutics plc has released preclinical data demonstrating the potential of its novel antibody-drug conjugate (ADC) spliceosome modulating payload, PH1, for the treatment of tumors driven by ...

Primary hyperoxaluria type 1 (PH1), an orphan disease caused by AGXT mutations, leads to increased oxalate production, stones, nephrocalcinosis, and kidney failure. The recently approved ...